Abstracts tagged "patient-reported outcome measures and axial spondyloarthritis"

Abstract Number: 1083 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Johan Askling ², Anne Gitte Loft ³, Michael J. Nissen ⁴, Herman Mann ⁵, Haner Direskeneli ⁶, Florenzo Iannone ⁷, Joe Sexton ⁸, Dan Nordström ⁹, Maria José Santos ¹⁰, Catalin Codreanu ¹¹, Manuel Pombo-Suarez ¹², Ziga Rotar ¹³, Bjorn Gudbjornsson ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Ulf Lindström ¹⁶, Adrian Ciurea ¹⁷, Karel Pavelka ⁵, Neslihan Yilmaz ¹⁸, Elisa Gremese ¹⁹, Eirik Kristianslund ²⁰, Anna Mari Hokkanen ²¹, Anabela Barcelos ²², Ruxandra IONESCU ²³, Carlos Sánchez-Piedra ²⁴, Matija Tomsic ²⁵, Arni Jon Geirsson ²⁶, Marleen van de Sande ¹⁵, Gary Macfarlane ²⁷, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁴University Hospital Geneva, Geneva, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶TURKBIO registry and Marmara University School of Medicin, Division of Rheumatology, Istanbul, Turkey, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁹Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ¹⁰Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹¹Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹²Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹³UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁴Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶University of Gothenburg, Gothenburg, Sweden, ¹⁷University Hospital Zürich, Zürich, Switzerland, ¹⁸TURKBIO registry and Bilim University School of Medicin, Division of Rheumatology, Istanbul, Turkey, ¹⁹Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ²⁰Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ²¹Helsinki University Hospital, Helsinki, Finland, ²²Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁵Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ²⁶Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Treatment effectiveness in patients with axial spondylarthritis (axSpA) is evaluated by a combination of objective markers of disease activity and patient reported outcomes (PROs),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].